|
**Overview**: Dengue Antibodies Panel**Introduction**: The Dengue Antibodies Panel is a diagnostic tool designed to screen for dengue infection using serum samples. In India, dengue is endemic with annual outbreaks (millions of cases, thousands of deaths), caused by DENV 1-4, presenting with fever, myalgia, rash, and severe forms (DHF/DSS) in secondary infections. IgM indicates recent infection; IgG past exposure or secondary infection. High morbidity from underdiagnosis in rural monsoon areas, limited serology access, delayed supportive care leading to shock or hemorrhage. Per microbiology practices aligned with ICMR and NVBDCP guidelines, the test employs immunoassay for IgG/IgM over 1-2 days with high sensitivity/specificity, valuable for confirmation in febrile illness. This diagnostic falls under viral screening and targets patients with fever, thrombocytopenia, or outbreak exposure, addressing accurate detection to guide fluid management and warning sign monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing severe dengue burden. Its serum-based approach ensures reliable detection.**Other Names**: Dengue Ab Pnl.**FDA Status**: FDA approved, CLIA certified for immunology/microbiology, compliant with 2025 standards.**Historical Milestone**: Dengue serology standard; in India, key in outbreak response.**Purpose**: The test screens for 2 parameters including dengue IgG and IgM to guide infection assessment, detect acute/past exposure, inform management.**Test Parameters**: 1. Dengue IgG, 2. Dengue IgM.**Pretest Condition**: No fasting required; patients should report fever, rash, joint pain, or mosquito exposure.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fever duration, rash, bleeding, travel history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated dengue including severe forms, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or cross-reactivity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM indicates acute dengue; IgG rise suggests secondary infection, necessitating specialist input. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Infectious disease specialists should be consulted for management.**Additional Supporting Tests**: NS1 antigen, PCR for confirmation.**Test Limitations**: IgM may persist; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, Dengue Studies India 2023. |
